How much revenue does Emcure Pharmaceuticals L make?

Emcure Pharmaceuticals L reported 78.08 billion INR in revenue for fiscal year 2025, up 18.6% from 65.82 billion INR in fiscal year 2024. In Q2 2026 revenue was 22.70 billion INR.

What companies are similar to Emcure Pharmaceuticals L?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS), Ajanta Pharma Limited (AJANTPHARM.NS), J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS), Wockhardt Limited (WOCKPHARMA.NS).

Emcure Pharmaceuticals L (EMCURE.NS) Stock

About Emcure Pharmaceuticals L

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides i...

At a glance

Emcure Pharmaceuticals L reported revenue of 78.08 billion INR for fiscal year 2025, up 18.6% from fiscal year 2024, and net income of 6.81 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 22.70 billion INR, up 13.4% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.